In the first part of a two-part interview, Paz Vellanki of Precision for Medicine explains what sponsors should bring to early FDA meetings and how manufacturing and assay readiness can delay rare disease trials.
|Articles|April 30, 2020
INTERPHEX Rescheduled for 2021 Due to COVID-19
Author(s)BioPharm International Editors
The event will be rescheduled for April 20–22, 2021 at the Javits Center in New York City.
Advertisement
Reed Exhibitions announced on April 30, 2020 that it was rescheduling its pharmaceutical industry event, INTERPHEX - previously postponed to July 15–17 at the Javits Center in New York City - to April 20–22, 2021 at the same venue due to the continuing spread of COVID-19.
“Our entire team is here to support all of our customers and partners and we are passionate about providing new options for us to come together, virtually throughout the summer and with smaller face-to-face interactions opportunities in the fall, when we can. Stay tuned for more information coming soon,” said Kate Scott, event director, INTERPHEX, in a press release.
The announcement comes days after INTERPHEX announced the launch of RECONNEX 365, an online resource that provides exhibitor expertise and technical know-how year-round.
“You will see even more tools, resources, and innovative solutions coming from the INTERPHEX team,” added Scott in the press release. “These will allow you to make new connections; meet leading suppliers; source technologies, products, and services; and learn from industry subject matter experts to enable you to find solutions to develop and manufacture cost-effective, quality therapeutics for the global population.”
Source:
Advertisement
Related to this article
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
Detalimogene voraplasmid produced a 56% complete response rate in BCG-unresponsive bladder cancer, with an estimated 43% of responses lasting a year.
FDA has cleared Biolojic Design’s IND for BD200, a bispecific antibody-drug conjugate targeting Trop2 and Nectin-4 whose arms can each bind either target. A global Phase 1 study in solid tumors is expected to begin in the coming weeks.
Blackstone Life Sciences will fund up to $1.5 billion of development costs through 2028 for Pfizer’s monthly GLP-1 receptor agonist berobenatide, in exchange for milestone payments tied to approval and sales. Pfizer keeps full control of the program.
Gene-corrected nula-cel freed all 3 RESTORE patients from transfusions, with sickle hemoglobin below 20% in the 2 followed for over 6 months.
Beam Therapeutics’ base-edited cell therapy risto-cel meets its primary endpoint in the BEACON sickle cell disease trial, Amgen’s CD40L antagonist dazodalibep reduces systemic disease activity in the phase 3 OASIZ-301 Sjögren’s disease trial, and ImvivaBio’s allogeneic CD19/BCMA CAR-T CTA313 sustains lupus remission through 12 months.
Matt Truppo, Richard Jaenisch, and Brian Drapeau examine AI's impact on drug success, human oversight, data governance, and biopharma's future.
Advertisement
Advertisement
Trending on BioPharm International
1
ImvivaBio’s Dual-Target Allogeneic CAR-T Sustains Lupus Remission Through 12 Months
2
Updates on Simtra BioPharma Solutions’ Bloomington Capacity Expansions
3
Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Berobenatide Development
4
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
5